Ji WB, et al. - Authors here compared the survival rates and complications experienced by patients receiving either 4 or 6 months of FOLFOX chemotherapy for stage II and III colon cancer. The 2 groups were not significantly different in terms of five-year overall and disease-free survival. They identified the necessity for large-scale prospective studies for the analysis of complications and survival rates.